These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

56 related items for PubMed ID: 3804368

  • 1. A biological approach to optimize interferon treatment in hairy cell leukemia.
    Gastl G, Aulitzky W, Tilg H, Nachbaur K, Troppmair J, Flener R, Huber C.
    Immunobiology; 1986 Sep; 172(3-5):262-8. PubMed ID: 3804368
    [Abstract] [Full Text] [Related]

  • 2. Comparison of clinical efficacy and toxicity of conventional and optimum biological response modifying doses of interferon alpha-2C in the treatment of hairy cell leukemia: a retrospective analysis of 39 patients.
    Gastl G, Werter M, De Pauw B, Nerl C, Aulitzky W, von Lüttichau I, Tilg H, Thaler J, Lang A, Abbrederis K.
    Leukemia; 1989 Jun; 3(6):453-60. PubMed ID: 2725061
    [Abstract] [Full Text] [Related]

  • 3. [Results of a phase II study on the treatment of hairy cell leukemias with various doses of alpha-2-recombinant interferon].
    Aulitzky W, Gastl G, Troppmair J, Tilg H, Abbrederis K, Nerl C, Flener R, Rokos H, Huber C.
    Acta Med Austriaca; 1985 Jun; 12(5):115-21. PubMed ID: 3832745
    [Abstract] [Full Text] [Related]

  • 4. Studies on the optimal dose and the mode of action of alpha-interferon in the treatment of hairy cell leukemia.
    Huber C, Aulitzky W, Tilg H, von Lüttichau I, Troppmair J, Nachbauer K, Gastl G.
    Leukemia; 1987 Apr; 1(4):355-7. PubMed ID: 3669762
    [Abstract] [Full Text] [Related]

  • 5. [Interferon-alpha in the treatment of hematologic neoplasms].
    Aulitzky W, Gastl G, Tilg H, Troppmair J, Leiter E, Geissler D, Flener R, Huber C.
    Wien Med Wochenschr; 1986 Apr 30; 136(7-8):172-81. PubMed ID: 3524022
    [Abstract] [Full Text] [Related]

  • 6. The importance of patient monitoring in clinical cytokine trials: use of serum markers to define biologically active doses.
    Huber C, Herold M.
    Cancer Surv; 1989 Apr 30; 8(4):809-15. PubMed ID: 2518331
    [Abstract] [Full Text] [Related]

  • 7. IFN-beta induced biochemical and immunological modifications in hairy cell leukemia patients.
    Liberati AM, Schippa M, Portuesi MG, Grazia Proietti M, De Angelis V, Ferrajoli A, Cinieri S, Di Clemente F, Palmisano L, Berruto P.
    Haematologica; 1991 Apr 30; 76(5):375-82. PubMed ID: 1806440
    [Abstract] [Full Text] [Related]

  • 8. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies.
    Steis RG, Smith JW, Urba WJ, Clark JW, Itri LM, Evans LM, Schoenberger C, Longo DL.
    N Engl J Med; 1988 Jun 02; 318(22):1409-13. PubMed ID: 3367950
    [Abstract] [Full Text] [Related]

  • 9. The UCLA experience with type I interferons in hairy cell leukemia.
    Glaspy JA, Jacobs AD, Golde DW.
    Leukemia; 1987 Apr 02; 1(4):323-6. PubMed ID: 3312839
    [Abstract] [Full Text] [Related]

  • 10. Recombinant alpha-2 interferon in the treatment of hairy cell leukemia.
    Thompson JA, Brady J, Kidd P, Fefer A.
    Cancer Treat Rep; 1985 Apr 02; 69(7-8):791-3. PubMed ID: 4016788
    [Abstract] [Full Text] [Related]

  • 11. [Use of alpha-interferon in the treatment of patients with hairy cell leukemia].
    Gotić M, Rolović Z, Vuković S, Elezović I, Tomić D.
    Srp Arh Celok Lek; 1990 Apr 02; 118(7-8):277-84. PubMed ID: 2097776
    [Abstract] [Full Text] [Related]

  • 12. The U.K. experience with human lymphoblastoid interferon in HCL: a report of the first 50 cases.
    Worman CP, Catovsky D, Cawley JC, Bevan PC, Bottomley JM, Nethersell AB.
    Leukemia; 1987 Apr 02; 1(4):320-2. PubMed ID: 3669754
    [Abstract] [Full Text] [Related]

  • 13. Low-dose interferon alfa-2b in the treatment of hairy cell leukemia.
    Moormeier JA, Ratain MJ, Westbrook CA, Vardiman JW, Daly KM, Golomb HM.
    J Natl Cancer Inst; 1989 Aug 02; 81(15):1172-4. PubMed ID: 2746669
    [Abstract] [Full Text] [Related]

  • 14. Alpha interferon for induction of remission in hairy-cell leukemia.
    Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU.
    N Engl J Med; 1984 Jan 05; 310(1):15-8. PubMed ID: 6689734
    [Abstract] [Full Text] [Related]

  • 15. Treatment of hairy cell leukemia with increasing doses of recombinant alpha A interferon.
    Holmes R, Schwarz MA, Whiteside MG, Firkin FC.
    Aust N Z J Med; 1988 Jun 05; 18(4):557-62. PubMed ID: 3196242
    [Abstract] [Full Text] [Related]

  • 16. Rapid improvement in a terminal case of hairy cell leukemia treated with a new human recombinant interferon, IFN-alpha-C.
    Aderka D, Levo Y, Rahmani R, Mory Y, Vaks B, Horowitz O, Doerner T, Shoham J, Wallach D, Revel M.
    Isr J Med Sci; 1985 Dec 05; 21(12):977-81. PubMed ID: 4093298
    [Abstract] [Full Text] [Related]

  • 17. In vitro induction of proteins by alpha-interferon in hairy cell leukemia.
    Samuels BL, Golomb HM, Brownstein BH.
    Cancer Res; 1986 Aug 05; 46(8):4151-5. PubMed ID: 3731082
    [Abstract] [Full Text] [Related]

  • 18. Treatment of hairy cell leukaemia with recombinant alpha interferon.
    Romeril KR, Carter JM, Green GJ, Beard ME, Heaton DC, Newhook CH, Gibbons SS, Reddy J.
    N Z Med J; 1989 Apr 26; 102(866):186-8. PubMed ID: 2652008
    [Abstract] [Full Text] [Related]

  • 19. Loss of interferon antibodies during prolonged continuous interferon-alpha 2a therapy in hairy cell leukemia.
    Steis RG, Smith JW, Urba WJ, Venzon DJ, Longo DL, Barney R, Evans LM, Itri LM, Ewel CH.
    Blood; 1991 Feb 15; 77(4):792-8. PubMed ID: 1704264
    [Abstract] [Full Text] [Related]

  • 20. Treatment of hairy cell leukemia with alpha interferons.
    Quesada JR, Gutterman JU, Hersh EM.
    Cancer; 1986 Apr 15; 57(8 Suppl):1678-80. PubMed ID: 3948137
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.